Lunch Symposium Wednesday, June 4, 2008 12:30h - 14:00h Lower Ballroom Lunch will be provided
12:30 h   Chairman's/Co-chairman's introduction David Lillicrap, Kingston Erik Berntorp, Malmö 12:35 h   Inhibitors in haemophilia A patients with poor prognosis: role of VWF in the immune tolerance induction (ITI) Wolfhart Kreuz, Frankfurt 12:50 h   Can thrombin generation assay and inhibitor profile help optimize individual ITI treatment? Erik Berntorp, Malmö 13:00 h   Treatment of haemophilia A patients with inhibitors and a poor prognosis in Russia: octanate® ITI Nadejda Zozulya, Moscow 13:15 h   Treatment of Factor VIII-Inhibitors with octanate® in the UK Sabita Rangarajan, London 13:25 h   octanate® in ITI: single center experience Kate Khair, London 13:35 h   Study of the immunological markers in patients undergoing ITI Sebastien Lacroix-Desmazes, Paris 13:45 h   Incidence of FVIII inhibitors in PUPs treated with octanate®: an update from the prospective GTH-PUP study Carmen Escuriola, Frankfurt 13:55 h   Concluding remarks and discussion	Von Willebrand factor in FVIII complex concentrates: from laboratory to clinical practice Development of inhibitors to coagulation factor VIII (FVIII) is one of the major problems faced by people with haemophilia A. There is increasing evidence suggesting that FVIII/von Willebrand factor (VWF) complex concentrates may have less immunogenicity with respect to those plasma-derived concentrates purified with monoclonal antibodies and recombinant FVIII concentrates. The presence of VWF in FVIII concentrates might influence the FVIII-inhibitor development in previously untreated haemophilia A patients (PUPs), as well as the the clinical outcome of immune tolerance induction (ITI) - the only proven strategy for achieving FVIII-inhibitor eradication. This symposium will offer a balanced mix of clinical preclinical and basic data on the role of VWF in FVIII concentrates. The topics of the symposium will highlight the impact of VWF on FVIII-inhibitor immunology as well as the benefits of VWFcontaining FVIII concentrates to generate thrombin in FVIII-deficient inhibitor plasmas. In addition, most recent prospective and retrospective clinical data obtained with different classes of FVIII-concentrates used for ITI-treatment will be compared. The symposium will also provide an opportunity for discussing recent successful interim data from the prospective post-marketing study in progress, supporting the use of VWF/FVIII concentrate for ITI in haemophilia A patients with poor prognosis. Finally, an update on the progress of the ongoing prospective Good Clinical Practice clinical trial designed to further investigate the risk of FVIII-inhibitor development in PUPs treated with VWF/FVIII concentrate will be presented. Don't miss our other symposium: "Looking for milestone improvements in VWD treatment - tasks defined and resolved" at 07:00h - 08:30h on Tuesday, June 3, 2008.